Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cefepime: the next generation?

C C Sanders1

  • 1Department of Medical Microbiology, Creighton University School of Medicine, Omaha, Nebraska 68178.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|September 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cefepime : The Last Generation or the First Enhanced-Potency Broad Spectrum Cephalosporin?

Clinical drug investigation·2016
Same author

Potential impact of the VITEK 2 system and the Advanced Expert System on the clinical laboratory of a university-based hospital.

Journal of clinical microbiology·2001
Same author

Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae.

The Journal of antimicrobial chemotherapy·2001
Same author

Mechanisms responsible for cross-resistance and dichotomous resistance among the quinolones.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2001
Same author

Ability of the VITEK 2 advanced expert system To identify beta-lactam phenotypes in isolates of Enterobacteriaceae and Pseudomonas aeruginosa.

Journal of clinical microbiology·2000
Same author

A pilot study of antibiotic cycling in a hematology-oncology unit.

Infection control and hospital epidemiology·2000
Same journal

Reconsidering ambiguous language in infectious disease consult recommendations.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Antibiotic Treatment Duration for Uncomplicated Monomicrobial Enterococcal Bloodstream Infection: A Multicenter Target Trial Emulation.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Larger Blood Volume Increases Detection of Fastidious Mycobacteria and Fungi in Blood Culture.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Anticalcitonin: Limited utility of a context-dependent biomarker demonstrated in another real-world data set.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Procalcitonin Testing in Community-Acquired Pneumonia.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Wanted: A Relevant Correlate of Protection for Dengue Vaccines.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
See all related articles

Cefepime, a novel cephalosporin antibiotic, demonstrates enhanced potency and a broader spectrum of activity. Its unique molecular properties allow for improved gram-negative cell penetration and resistance to beta-lactamases, suggesting potential clinical advantages.

Area of Science:

  • Pharmacology
  • Microbiology
  • Medicinal Chemistry

Background:

  • Cefepime represents a new generation of aminothiazolylacetamido cephalosporin antibiotics.
  • Existing cephalosporins have limitations in spectrum and potency against certain bacterial pathogens.

Purpose of the Study:

  • To elucidate the molecular properties contributing to cefepime's enhanced antimicrobial activity.
  • To compare cefepime's efficacy and resistance mechanisms against older cephalosporins.

Main Methods:

  • Analysis of cefepime's penetration into gram-negative bacterial cells.
  • Evaluation of cefepime's interaction with essential penicillin-binding proteins.
  • Assessment of cefepime's stability against various beta-lactamase enzymes, particularly Bush group 1.

Related Experiment Videos

Main Results:

  • Cefepime exhibits more rapid penetration of gram-negative cells compared to older cephalosporins.
  • The drug effectively targets multiple essential penicillin-binding proteins.
  • Cefepime demonstrates significant resistance to many beta-lactamases due to low enzyme affinity, especially Bush group 1 enzymes.
  • Derepression of beta-lactamases has a reduced impact on cefepime's in vitro activity.

Conclusions:

  • Cefepime possesses superior in vitro characteristics, including broader spectrum and greater potency.
  • Its molecular structure confers advantages in bacterial cell penetration and beta-lactamase stability.
  • Clinical trial data are crucial to validate these in vitro findings and confirm cefepime's therapeutic benefits.